489 results on '"Yamade, Mihoko"'
Search Results
2. Ustekinumab effectiveness in Crohn’s disease with lesions in the intestines
3. Influence of daily versus alternate-day dosing of vonoprazan on intragastric pH, serum gastrin, and the antiplatelet function of clopidogrel: Influence of alternate-day dosing of vonoprazan
4. Modified method of patency judgement using patency capsule prior to capsule endoscopy in clinical practice
5. Lymphocyte to monocyte ratio and serum albumin changes predict tacrolimus therapy outcomes in patients with ulcerative colitis
6. Effect of disease duration on fecal biomarkers in ulcerative colitis: a prospective cohort study
7. Further research on the clinical relevance of the ulcerative colitis colonoscopic index of severity for predicting 5-year relapse
8. Albumin change predicts failure in ulcerative colitis treated with adalimumab
9. Effects of pirenzepine on vonoprazan-induced gastric acid inhibition and hypergastrinemia
10. Predicting Ulcerative Colitis Relapse in Clinical Remission With Fecal Immunochemical Occult Blood Test or Prostaglandin E-Major Urinary Metabolite
11. Comparison of fecal calprotectin levels and endoscopic scores for predicting relapse in patients with ulcerative colitis in remission
12. Comparison between Prostaglandin E-major urinary metabolite and C-reactive protein levels to reflect endoscopic scores in patients with ulcerative colitis
13. C-reactive protein is superior to fecal biomarkers for evaluating colon-wide active inflammation in ulcerative colitis
14. Prevalence of UL97 gene mutations and polymorphisms in cytomegalovirus infection in the colon associated with or without ulcerative colitis
15. Effect of ulcerative colitis duration on the usefulness of immunochemical fecal occult blood test result as a disease activity biomarker
16. A rectal neuroendocrine tumor in a patient with Crohn’s disease: a case report and literature review
17. CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines
18. Both MLH1 deficiency and BRAFV600E mutation are a unique characteristic of colorectal medullary carcinoma: An observational study
19. Improvement in Ulcerative Colitis by Administration of Benralizumab for Comorbid Refractory Bronchial Asthma: A Novel Clinical Observation
20. Improvement in Ulcerative Colitis by Administration of Benralizumab for Comorbid Refractory Bronchial Asthma: A Novel Clinical Observation
21. The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy
22. Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation
23. Expectations for the Dual Therapy with Vonoprazan and Amoxicillin for the Eradication of H. pylori
24. Prostaglandin E-Major Urinary Metabolite Predicts Relapse in Patients With Ulcerative Colitis in Clinical Remission
25. Personalized Therapy in H. pylori Eradication
26. Prostaglandin E-major urinary metabolite versus fecal immunochemical occult blood test as a biomarker for patient with ulcerative colitis
27. The effect of early trough level of infliximab on subsequent disease course in patients with Crohn disease: A prospective cohort study
28. A comparison of two types of contrast media used in endoscopic retrograde cholangiopancreatography: A retrospective study
29. Comparison of effect of an increased dosage of vonoprazan versus vonoprazan plus lafutidine on gastric acid inhibition and serum gastrin
30. Decompressive laparotomy for abdominal compartment syndrome resulting from severe acute pancreatitis: a case report
31. Importance of eosinophilic infiltration of the colonic mucosa in ulcerative colitis patients who are refractory to maintenance therapy: A prospective, single-center study
32. Influence of low-dose proton pump inhibitors administered concomitantly or separately on the anti-platelet function of clopidogrel
33. One-day front-loading with four doses of rabeprazole followed by a standard twice-daily regimen provides sufficient acid inhibition in extensive metabolizers of CYP2C19
34. Effects of pirenzepine on vonoprazan-induced gastric acid inhibition and hypergastrinemia
35. Ability of Rabeprazole to Prevent Gastric Mucosal Damage From Clopidogrel and Low Doses of Aspirin Depends on CYP2C19 Genotype
36. Importance of Eosinophilic Infiltration of the Colonic Mucosa in Ulcerative Colitis Patients who are Refractory to Maintenance Therapy
37. Lymphocyte-to-monocyte ratio is a short-term predictive marker of ulcerative colitis after induction of advanced therapy
38. Lymphocyte-to-Monocyte Ratio as a Marker for Endoscopic Activity in Ulcerative Colitis
39. Usefulness of patency capsule prior to small-bowel capsule endoscopy in clinical practice: Validity of the modified method of patency judgement
40. Real-World Efficacy and Safety Monitoring for Predicting Continuation of Tofacitinib Therapy in Patients with Ulcerative Colitis
41. Usefulness of the capsule endoscopy Crohn's disease activity index in assessing the necessity of early additional treatment in patients with Crohn's disease in clinical remission
42. Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease
43. Influence of Prostate Stem Cell Antigen Gene Polymorphisms on Susceptibility to Helicobacter pylori-associated Diseases: A Case-control Study
44. Influence of clarithromycin on the bactericidal effect of amoxicillin in patients infected with clarithromycin-resistant strains of H. pylori
45. Effect of Ulcerative Colitis Duration on the Usefulness of Immunochemical Fecal Occult Blood Test Result as a Disease Activity Biomarker
46. Eradication of H. pylori infection in patients allergic to penicillin: O-057
47. Early serum albumin changes in patients with ulcerative colitis treated with tacrolimus will predict clinical outcome
48. Sa171 INFLUENCE OF DAILY OR ALTERNATE-DAY DOSING OF VONOPRAZAN ON INTRAGASTRIC PH, SERUM GASTRIN, AND THE ANTIPLATELET EFFECT OF CLOPIDOGREL; ADDITIONAL REPORT.
49. Sa238 CLASSIFICATION OF AUTOIMMUNE GASTRITIS BASED ON THE STATUS OF POLYGLANDULAR AUTOIMMUNE SYNDROME
50. Serum N-terminal telopeptide of type I collagen as a biomarker for predicting bone density loss in patients with Crohn disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.